{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years","groups":[{"description":"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.\n\nMelphalan will be given as a single dose (not split over 2 or more days) and given on day-1.\n\nDosing will be based on body surface area calculated using actual body weight","id":"OG000","title":"Auto Transplant High Dose Melphalan"},{"description":"Bortezomib:\n\nBortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.\n\nBortezomib: Bortezomib:\n\nBortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1.","id":"OG001","title":"Auto Transplant High Dose Melphalan+Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely","title":"Progression Free Survival Rate","type":"PRIMARY","unitOfMeasure":"Participants"}